Clinical Trial Update: Belimumab and Rituximab Combination Therapy for the Treatment of Diffuse Cutaneous Systemic Sclerosis [Phase 2]

View source ↗

Summary

This entry reports a Phase 2 clinical trial evaluating the combination of belimumab and rituximab for diffuse cutaneous systemic sclerosis, with recruitment sta…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Cutaneous Systemic Sclerosis
• Systemic Sclerosis

Drugs mentioned

• BENLYSTA (belimumab)
• Rituxan (rituximab)

Snippet

Sponsor: Hospital for Special Surgery, New York | Conditions: Systemic Sclerosis | Phase 2 | Status: RECRUITING